Sign in

Thomas G. Frinzi

President, CEO, and Chair of the Board at STAAR SURGICAL
Board
Since January 1, 2023
Age
68 years
Education
Earned a Bachelor of Arts (B.A.) from the University of Tampa.
Tenure
Joined STAA as a Board member in June 2020 , was appointed Chair of the Board in June 2022 , and assumed the role of President and CEO on January 1, 2023.

Also at STAAR SURGICAL

KHP
Keith Holliday, Ph.D.
Chief Technology Officer (CTO)
NBSE
Nathaniel B. Sisitsky, Esq.
General Counsel and Corporate Secretary
PFW
Patrick F. Williams
Chief Financial Officer (CFO)

About

Thomas G. Frinzi is 68 years old and has built a robust foundation in the ophthalmic and medical device sectors, where his leadership and innovative strategies have played a significant role in transforming the industry.

With extensive experience spanning multiple leadership roles at large corporations and start-ups alike, his career reflects a commitment to excellence in international sales, marketing, and executive management. His roles at companies such as Bausch & Lomb Surgical, WaveTec Vision, Abbott Medical Optics, and Johnson & Johnson Vision have equipped him with a deep operational and strategic insight into the challenges and opportunities of the ophthalmic field.

At STAA, his journey began when he joined as a Board member in June 2020, later progressing to Chair of the Board in June 2022, and culminating in his appointment as President and CEO on January 1, 2023. His tenure at the company is marked by a blend of visionary leadership and practical experience, driving growth and operational excellence in a competitive market.

$STAA Performance Under Thomas G. Frinzi

Past Roles

OrganizationRoleDate RangeDetails
STAAR Surgical Company (STAA) Chair of the Board June 2022 - December 2022 Appointed as Chair prior to becoming President & CEO
STAAR Surgical Company (STAA) Board Member June 2020 - June 2022 Served as a Board member before subsequent appointments
CorneaGen Executive Chair of the Board of Directors Joined August 2020 Oversaw development of therapeutics for corneal disease
Johnson & Johnson Vision Worldwide President, Surgical February 2017 - December 2019 Managed a broad ophthalmology portfolio
Abbott Medical Optics (AMO) Senior Vice President of Abbott Laboratories and President of AMO January 2016 - February 2017 AMO was acquired by Johnson & Johnson
Alcon Head of WaveTec Vision September 2014 - July 2015 Led continued leadership after acquisition of WaveTec Vision
WaveTec Vision President and CEO September 2010 - September 2014 Led development of surgical systems; later acquired by Alcon
Bausch & Lomb Surgical, Refractec, Chiron Vision, and Johnson & Johnson Senior Positions in Commercial Operations, Business Development, and Sales & Marketing N/A Held various senior roles

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$820,000 AnnualFixed base salary for 2023.
Severance Payment$1,230,000 18 monthly installments18 months of base salary if terminated without cause or if resigns for good reason.
COBRA Premiums$0 N/ADeclined health care benefits in 2023.

Performance Compensation

Data from  FY 2023

Annual Cash Bonus

MetricTarget / ValueAdditional Details
Revenue Target$355 million Revenue performance metric as set in the 2023 Bonus Plan.
Adjusted EBITDA per Share Target$1.30 EBITDA per Share performance target defined in the 2023 Bonus Plan.
Funding Level50% Due to actual results of $322.4M revenue and $1.15 EBITDA per share, the bonus pool was funded at 50%.
Base Salary$820,000 Base used for bonus calculation.
Target Bonus Percentage105% Bonus percentage based on base salary.
Target Bonus Amount$861,000 Calculated as 105% of the base salary.
Earned Bonus Payment$430,500 50% of the target bonus amount due to performance shortfall.

Note: The Annual Cash Bonus is part of STAAR's 2023 Bonus Plan, a non-equity incentive plan award without any related grant date, vesting schedule, or equity component.